ALDURAZYME
Drug
GENZYME CORPORATION
Total Payments
$970,118
Transactions
594
Doctors
230
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $56,745 | 60 | 25 |
| 2023 | $232,532 | 73 | 16 |
| 2022 | $23,902 | 25 | 18 |
| 2021 | $24,265 | 7 | 5 |
| 2020 | $16,014 | 14 | 7 |
| 2019 | $311,444 | 224 | 123 |
| 2018 | $222,944 | 94 | 33 |
| 2017 | $82,274 | 97 | 39 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $553,702 | 148 | 57.1% |
| Consulting Fee | $146,336 | 43 | 15.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $135,972 | 63 | 14.0% |
| Travel and Lodging | $116,149 | 64 | 12.0% |
| Food and Beverage | $15,460 | 273 | 1.6% |
| Space rental or facility fees (teaching hospital only) | $2,499 | 3 | 0.3% |
Payments by Type
Research
$553,702
148 transactions
General
$416,416
446 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| To examine the utility of NRE biomarkers in patients with MPS | GENZYME CORPORATION | $115,792 | 0 |
| Mucopolysaccharidosis I (MPS I) Registry | SANOFI US SERVICES INC. | $94,393 | 0 |
| The role of angiotensin II-mediated inflammation in MPS I vascular disease: a study of pathophysiologic mechanism and evaluation of angiotensin receptor blockade therapy | GENZYME CORPORATION | $69,266 | 0 |
| Pilot Study of Administration of Intravenous Laronidase Following Allogenic Transplantation for Hurler Syndrome | GENZYME CORPORATION | $64,371 | 0 |
| Post-Transplant Enzyme to Ameliorate Skeletal Dysplasia in MPS I Mice | GENZYME CORPORATION | $48,909 | 0 |
| Intrathecal Enzyme Replacement Therapy for Patients with Mucopolysaccharidosis Type I (Hurler Syndrome) | GENZYME CORPORATION | $48,830 | 0 |
| MPS I Disease Registry | GENZYME CORPORATION | $28,808 | 0 |
| Biomarkers of Inflammation, Bone Remodeling, and Cartilage Turnover to Predict Musculoskeletal Disease Progression in Hurler syndrome | GENZYME CORPORATION | $23,030 | 0 |
| Q1 2018 MPS1 LSD Registry | GENZYME CORPORATION | $21,870 | 0 |
| Q4 2017 MPSI LSD Registry | GENZYME CORPORATION | $13,306 | 0 |
| MPS-I Registry | GENZYME CORPORATION | $13,218 | 3 |
| Mucopolysaccharidosis I (MPS I) Registry | GENZYME CORPORATION | $7,267 | 3 |
| Q1 2018 MPSI LSD Registry | GENZYME CORPORATION | $1,325 | 0 |
| MPS I Registry | GENZYME CORPORATION | $1,250 | 1 |
| Q4 2017 Pompe LSD Registry | GENZYME CORPORATION | $575.00 | 0 |
| Q12018MPSI LSD Registry | GENZYME CORPORATION | $400.00 | 0 |
| Sanchez-Valle_61198078_Rare Disease Registry | GENZYME CORPORATION | $378.75 | 0 |
| Genzyme Rare Disease Registry | GENZYME CORPORATION | $300.00 | 0 |
| Q4 MPS LSD Registry | GENZYME CORPORATION | $150.00 | 0 |
| Sanchez-Valle_61198078-Rare Disease Registry | GENZYME CORPORATION | $138.75 | 0 |
Top Doctors Receiving Payments for ALDURAZYME — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , O.D | Optometrist | Richardson, TX | $121.95 | 1 |
| , OD | Optometrist | Carrollton, TX | $121.95 | 1 |
| , O.D | Optometrist | Cedar Hill, TX | $121.95 | 1 |
| , O.D | Optometrist | Irving, TX | $121.95 | 1 |
| , O.D | Optometrist | Dallas, TX | $121.95 | 1 |
| , O.D | Optometrist | Little Rock, AR | $121.95 | 1 |
| , O.D | Optometrist | Plano, TX | $121.35 | 1 |
| , O.D | Optometrist | Prosper, TX | $121.35 | 1 |
| , O.D | Optometrist | Greenville, TX | $121.35 | 1 |
| , O.D | Optometrist | Gainesville, TX | $121.35 | 1 |
| , O.D | Optometrist | Mesquite, TX | $121.35 | 1 |
| , O.D | Optometrist | Plano, TX | $121.35 | 1 |
| , OD | Corneal and Contact Management | Allen, TX | $121.35 | 1 |
| , MD | Family Medicine | Berryville, AR | $120.59 | 1 |
| , M.D., MPH | Family Medicine | Springdale, AR | $120.59 | 1 |
| , OD | Optometrist | Vestal, NY | $117.68 | 1 |
| , OD | Optometrist | Binghamton, NY | $117.68 | 1 |
| , OD | Optometrist | Cortland, NY | $117.68 | 1 |
| , M.D | Internal Medicine | Augusta, GA | $113.85 | 1 |
| , O.D | Optometrist | Centennial, CO | $113.85 | 1 |
| , MD | Ophthalmology | Denver, CO | $113.85 | 1 |
| , O. D | Optometrist | Westminster, CA | $113.38 | 1 |
| , O.D | Optometrist | Garden Grove, CA | $113.38 | 1 |
| , O.D | Optometrist | Santa Ana, CA | $113.38 | 1 |
| , O.D | Optometrist | Orange, CA | $113.38 | 1 |
Ad
Manufacturing Companies
- GENZYME CORPORATION $758,662
- SANOFI-AVENTIS U.S. LLC $117,063
- SANOFI US SERVICES INC. $94,393
Product Information
- Type Drug
- Total Payments $970,118
- Total Doctors 230
- Transactions 594
About ALDURAZYME
ALDURAZYME is a drug associated with $970,118 in payments to 230 healthcare providers, recorded across 594 transactions in the CMS Open Payments database. The primary manufacturer is GENZYME CORPORATION.
Payment data is available from 2017 to 2024. In 2024, $56,745 was paid across 60 transactions to 25 doctors.
The most common payment nature for ALDURAZYME is "Unspecified" ($553,702, 57.1% of total).
ALDURAZYME is associated with 20 research studies, including "To examine the utility of NRE biomarkers in patients with MPS" ($115,792).